 An alternative approach to providing controlled anticoagulation embraced by Regado Biosciences is the utilization of an anticoagulating agent with medium-term duration of action 12 hours that can achieve clinically appropriate activity at relatively low doses, in combination with a second agent capable of specifically binding to and neutralizing the primary anticoagulant. Such a drug-antidote combination can ensure predictable and safe neutralization and reversal of the anticoagulant activity of the drug Rusconi et al., 2004; Rusconi et al., 2002. 